definiens: shall mean with respect to any period prior to July 1, 2010, an amount equal to ( CONFIDENTIAL TREATMENT REQUESTED ) ( ) of Net Sales during such period of Licensee 's monoclonal a ntibody(ies ) that are Royalty Bearing Product, including, but not limited to, Synagis ® in the Unit ed States . On July 1, 2010, Licensor and Licensee will reset the Applicable Percentage by taking the actual Net Sales by month of Licensee 's monoclonal antibody(ies ) that are Royalty Bearing Product incl uding, but not limited to, Synagis ® sold for use within the Commonwealth of Massachusetts and the St ate of Maine during the twelve ( 12 ) month period immediately proceeding such date ( [COMPANY] to schedule its actual sales of Synagis ® in good faith ), and dividing by the actual Net Sales of Lic ensee 's monoclonal antibody(ies ) that are Royalty Bearing Product including, but not limited to, Syna gis ® within the United States during the same twelve ( 12 ) month period . Such reset procedure will be repeated at the conclusion of each six - year period thereafter